Physician profile
Jae Kim
NPI 1861578759
$12,314.74
in general payments reported to CMS, 2019-2025
37 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,340 · 2020: $236 · 2021: $790 · 2022: $835 · 2023: $775 · 2024: $972 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,066 · Education: $47.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.30 |
| Education | $47.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,838.79 | 2019 | |
| Abbvie INC. | $1,330.05 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $552.43 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $547.00 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $366.56 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Boston Scientific Corporation | $316.82 | 2024-2025 | Rezum Generator, Exalt Model D, Overstitch Endoscopic Suturing System |
| Daiichi Sankyo INC. | $286.35 | 2019-2022 | |
| Celgene Corporation | $215.59 | 2021-2023 | Zeposia |
| Genzyme Corporation | $165.57 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $150.55 | 2024-2025 | Voquezna |
| Pfizer INC. | $149.49 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $125.79 | 2021-2025 | Ocaliva |
| Evoke Pharma, INC. | $124.94 | 2021-2025 | Gimoti |
| Ardelyx, INC. | $106.10 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $103.92 | 2021-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $102.20 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $99.46 | 2023-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $96.36 | 2025 | Iqirvo |
| Laborie Medical Technologies Corp. | $89.76 | 2021 | |
| Madrigal Pharmaceuticals | $76.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $61.20 | 2021-2022 | |
| Qol Medical, LLC | $52.97 | 2024-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $40.75 | 2023-2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.31 | 2023 | Cyltezo |
| Averitas Pharma INC. | $36.93 | 2024 | Qutenza |
| Ferring Pharmaceuticals INC. | $35.64 | 2023 | Rebyota |
| Edwards Lifesciences Corporation | $27.79 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $26.21 | 2023 | |
| Ucb, INC. | $25.48 | 2019 | |
| Biocon Biologics INC | $23.51 | 2025 | Yesintek |
| Mauna Kea Technologies, INC. | $23.41 | 2025 | |
| Neurocrine Biosciences, INC. | $19.60 | 2024 | Ingrezza |
| Intra-Sana Laboratories | $16.32 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Amgen INC. | $15.11 | 2021 | |
| Shire North American Group INC | $13.81 | 2019 | |
| Fresenius Kabi USA, LLC | $12.95 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jae Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.